The US Food and Drug Administration (FDA) is strengthening existing warnings about serious behavior and mood-related changes with montelukast (Singulair; Merck and generics), which is used to treat ...
A 14-day course of the oral anti-inflammatory drug montelukast didn't shorten symptom duration in nonhospitalized US adults with mild or moderate COVID-19, finds a randomized controlled clinical trial ...
Asthma and allergy drug montelukast—sold as a generic and under the brand name Singulair—will get a "boxed warning" over potential ties to neuropsychiatric effects, the U.S. Food and Drug ...
Australia’s Therapeutic Goods Administration (TGA) recently issued a safety alert requiring extra warnings to be included with the asthma and hay fever drug montelukast. The warnings are for users and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results